Five Prime Bounces Back With Good Spin On Cabiralizumab Data

 
• By Emily Hayes

Bristol's new Phase I study of Opdivo with Five Prime's cabiralizumab in second-line pancreatic cancer restored faith in the combo for some investors, as did a full presentation of pancreatic cancer data slated for SITC.

Stock exchange graph screen electronic company corporate index display profit economic global graphic loss succes

More from Anticancer

More from Therapy Areas